Volume 15, Issue 5, Pages (May 2007)

Slides:



Advertisements
Similar presentations
Volume 15, Issue 6, Pages (June 2007)
Advertisements

Volume 16, Issue 3, Pages (March 2008)
Volume 24, Issue 7, Pages (July 2016)
by Elena A. Federzoni, Peter J. M. Valk, Bruce E
Volume 15, Issue 6, Pages (June 2012)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Molecular Therapy - Nucleic Acids
Mechanisms of p53 Restriction in Merkel Cell Carcinoma Cells Are Independent of the Merkel Cell Polyoma Virus T Antigens  Roland Houben, Christina Dreher,
N. Zhong, J. Sun, Z. Min, W. Zhao, R. Zhang, W. Wang, J. Tian, L
Demián Cazalla, Mingyi Xie, Joan A. Steitz  Molecular Cell 
Alleviation of Toxicity Caused by Overactivation of Pparα through Pparα-Inducible miR- 181a2  Yanjie Cheng, Zhuying Wei, Shengsong Xie, You Peng, Yi Yan,
Volume 16, Issue 1, Pages (January 2008)
The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation  Rixun Fang, Nilda A. Santiago, Lynne C. Olds,
Masanori Ono, M. D. , Ph. D. , Ping Yin, Ph. D. , Antonia Navarro, M
Mechanisms of p53 Restriction in Merkel Cell Carcinoma Cells Are Independent of the Merkel Cell Polyoma Virus T Antigens  Roland Houben, Christina Dreher,
Volume 15, Issue 1, Pages (January 2007)
Volume 19, Issue 4, Pages (April 2011)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed.
Volume 10, Issue 1, Pages (July 2004)
Stefan W. Stoll, Jessica L. Johnson, Yong Li, Laure Rittié, James T
Tyrosinase-Based Reporter Gene for Photoacoustic Imaging of MicroRNA-9 Regulated by DNA Methylation in Living Subjects  Haifeng Zheng, Lin Zhou, Yaru.
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)‏ by Michaela Scherr, Anuhar Chaturvedi, Karin.
Volume 13, Issue 2, Pages (February 2006)
Molecular Therapy - Methods & Clinical Development
Volume 22, Issue 2, Pages (February 2014)
Volume 50, Issue 3, Pages (May 2013)
Robert Schickel, Sun-Mi Park, Andrea E. Murmann, Marcus E. Peter 
Slicing-Independent RISC Activation Requires the Argonaute PAZ Domain
Jun Zhan, Irudayam Maria Johnson, Matthew Wielgosz, Arthur W Nienhuis 
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Volume 7, Issue 2, Pages (August 2016)
Generation of a stable packaging cell line producing high-titer PPT-deleted integration- deficient lentiviral vectors  Peirong Hu, Yedda Li, Mark S Sands,
Volume 15, Issue 9, Pages (September 2007)
Multiple Functions of the 37/67-kd Laminin Receptor Make It a Suitable Target for Novel Cancer Gene Therapy  Jonathan Scheiman, Jen-Chieh Tseng, Yun Zheng,
Volume 16, Issue 24, Pages (December 2006)
Molecular Therapy - Nucleic Acids
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas
Volume 127, Issue 4, Pages (October 2004)
Volume 5, Issue 3, Pages (November 2013)
MicroRNA Destabilization Enables Dynamic Regulation of the miR-16 Family in Response to Cell-Cycle Changes  Olivia S. Rissland, Sue-Jean Hong, David P.
Volume 133, Issue 4, Pages (May 2008)
Nef Triggers a Transcriptional Program in T Cells Imitating Single-Signal T Cell Activation and Inducing HIV Virulence Mediators  Alison Simmons, Varuna.
RNA Polymerase II Activity of Type 3 Pol III Promoters
Molecular Therapy - Nucleic Acids
Volume 15, Issue 4, Pages (April 2007)
Diverse Herpesvirus MicroRNAs Target the Stress-Induced Immune Ligand MICB to Escape Recognition by Natural Killer Cells  Daphna Nachmani, Noam Stern-Ginossar,
Volume 27, Issue 6, Pages (September 2007)
Transcriptional Repression of miR-34 Family Contributes to p63-Mediated Cell Cycle Progression in Epidermal Cells  Dario Antonini, Monia T. Russo, Laura.
Fiona T van den Berg, John J Rossi, Patrick Arbuthnot, Marc S Weinberg 
Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease  Ryan L Boudreau,
Volume 18, Issue 9, Pages (September 2010)
Molecular Therapy - Nucleic Acids
Volume 24, Issue 10, Pages (October 2016)
Enhanced Tailored MicroRNA Sponge Activity of RNA Pol II-Transcribed TuD Hairpins Relative to Ectopically Expressed ciRS7-Derived circRNAs  Anne Kruse.
The Human DiGeorge Syndrome Critical Region Gene 8 and Its D
Volume 22, Issue 9, Pages (September 2014)
Volume 2, Issue 4, Pages (October 2000)
Volume 20, Issue 11, Pages (November 2012)
Molecular Therapy - Nucleic Acids
Ryan L Boudreau, Inês Martins, Beverly L Davidson  Molecular Therapy 
Volume 15, Issue 9, Pages (September 2007)
Volume 21, Issue 3, Pages (March 2013)
Volume 23, Issue 4, Pages (April 2015)
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
Volume 11, Issue 5, Pages (May 2005)
Human Argonaute2 Mediates RNA Cleavage Targeted by miRNAs and siRNAs
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Presentation transcript:

Volume 15, Issue 5, Pages 938-945 (May 2007) A Facile Lentiviral Vector System for Expression of Doxycycline-Inducible shRNAs: Knockdown of the Pre-miRNA Processing Enzyme Drosha  Lars Aagaard, Mohammed Amarzguioui, Guihua Sun, Luis C Santos, Ali Ehsani, Hans Prydz, John J Rossi  Molecular Therapy  Volume 15, Issue 5, Pages 938-945 (May 2007) DOI: 10.1038/sj.mt.6300118 Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 1 Design and validation of the pFRT-based inducible knockdown system. (a) Insertion of a single tet repressor operon (tetO) into the 3′ end of the human U6 promoter using a pFRT plasmid backbone. Transcriptional start site indicated by uppercase G (bold), which is re-introduced by oligo-mediated short hairpin RNA (shRNA) cloning using the engineered BglII site (underlined). (b) Western blot analysis of protein kinase R (PKR) in HEK293 Flp-In TRex cells stably transfected with the pFRT plasmid utilizing either U6tetO- or H1tetO-promoted shRNAs targeting PKR, with or without doxycycline (dox) induction (3 days). (c) Northern blot analysis of Drosha mRNA in HEK293 Flp-In TRex cells stably transfected with the pFRT plasmid utilizing U6tetO-promoted shRNAs targeting Drosha, with or without dox induction. GAPDH was probed as an internal control. (d) Dose-dependent silencing of Drosha mRNA by northern blot analysis (upper panel) and northern analysis of induction of Drosha-targeting shRNAs (probing for the siRNA guide strand). Molecular Therapy 2007 15, 938-945DOI: (10.1038/sj.mt.6300118) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 2 Design and validation of lentiviral-based inducible knockdown system in transduced HEK293 cells. (a) Northern analysis of siRNA guide strand expression with varying doxycycline (dox) doses and induction times. Lanes 1–2, un-induced; lanes 3–6, induced with 37, 111, 333, and 1,000 ng/ml dox for 48 hours, respectively; lanes 7–10, 1,000 ng/ml dox induction for 24, 12, 6, and 3 hours, respectively. U6 snRNA was probed as an internal RNA loading control. A long-term exposure of lanes 1–3 is shown in the lower panel. (b) Dox-dependent silencing of a transiently transfected shDr-sensitive Renilla luciferase reporter (psiCheck-Dr) after standardization to the internal Firefly luciferase control. Cells treated with 1 μg/ml dox 24 hours before reporter transfection. Values relative to un-treated shPKR transduced cells. (c) Schematic diagram of the pHIV-7-derived lentiviral vector pTIG (pHIV7-TetR-IRES-GFP) encoding a U6tetO-promoted short hairpin RNA (shRNA) cassette. CMV, cytomegalovirus promoter; eGFP, enhanced green fluorescent protein; IRES, internal ribosome entry site; psi, packaging signal; RRE, Rev response element; TetR, tetracycline regulatory protein; WPRE, woodchuck hepatitis virus post-transcription regulatory element. Molecular Therapy 2007 15, 938-945DOI: (10.1038/sj.mt.6300118) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 3 Silencing of endogenous Drosha in pTIG-U6tetO-transduced HEK293 cells. (a) Real-time quantitative polymerase chain reaction (PCR) of Drosha messenger RNA (mRNA) after prolonged dox treatment (1 μg/ml for 8 days) after normalization to GAPDH mRNA. Values are relative to un-treated shPKR-transduced cells. (b) Western blot analysis of Drosha protein after prolonged dox treatment. Molecular Therapy 2007 15, 938-945DOI: (10.1038/sj.mt.6300118) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 4 Reduction of mature microRNAs (miRNAs) after Drosha knockdown in pTIG-U6tetO-transduced HEK293 cells. (a) Northern blot analysis of mature miRNAs expressed after prolonged doxycycline (dox) treatment (1 μg/ml for 8 days). U6 snRNA was probed as an internal RNA loading control. (b) Dox-dependent de-repression of a transiently transfected miR-21-sensitive Renilla luciferase reporter that can either be cleaved by RISC (psiCheck-miR21-Perfect) or undergo miRNA-mediated translational inhibition in an miR-21-dependent manner (psiCheck-miR21-3xBulge). Cells were treated for 8 days with 1 μg/ml dox before reporter transfection. Renilla luciferase values were standardized to the internal Firefly luciferase control and represented relative to un-treated shPKR-transduced cells. P value indicated. (c) Phase contrast images (×100 magnification) of pTIG-U6tetO-shDr-transduced cells grown in the presence or absence of doxycycline for 8 days, then seeded at equal density (low = 5.3 × 105 cells per cm2, high = 1.6 × 106 cells per cm2) and subsequently grown for an additional 2 days. Hemocytometer counts of trypan blue–excluded cells 48 hour after seeding are indicated for the “low density” seeded cells (cells per cm2 ± SD, n = 3). Molecular Therapy 2007 15, 938-945DOI: (10.1038/sj.mt.6300118) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions